Psychosocial Impact of the Insulin-Only iLet Bionic Pancreas for Adults, Youth, and Caregivers of Youth with Type 1 Diabetes

the Bionic Pancreas Research Group

doi:10.1089/dia.2023.0238

Psychosocial Impact of the Insulin-Only iLet Bionic Pancreas for Adults, Youth, and Caregivers of Youth with Type 1 Diabetes

the Bionic Pancreas Research Group

Psychiatry and Behavioral Sciences

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

Objective: To evaluate the psychosocial impact and user experience for the insulin-only configuration of iLet bionic pancreas (BP) in persons 6–83 years years of age with type 1 diabetes. Research Design and Methods: In this multicenter, randomized controlled, 13-week trial, 275 adults (221 randomly assigned to the BP group and 54 to the standard of care [SC] group) and 165 youth and their caregivers (112 randomly assigned to the BP group and 53 to the SC group) completed psychosocial questionnaires at baseline, mid-study, and the end of the trial. Results: In all age groups, most participants would recommend using the BP, including those with previous experience using automated insulin delivery devices. Similarly, the vast majority of participants reported a high level of perceived benefits and a low number of perceived burdens. Adult participants reported significant decreases in the fear of hypoglycemia and in diabetes-specific emotional distress, as well as improvements in their perceived well-being. Conclusion: Findings demonstrate acceptability, reduced burden, and positive psychosocial outcomes for adults. Children and teenagers also report high acceptability and reduced burden, but less clear improvements in psychosocial outcomes.

Original language	English (US)
Pages (from-to)	705-717
Number of pages	13
Journal	Diabetes Technology and Therapeutics
Volume	25
Issue number	10
DOIs	https://doi.org/10.1089/dia.2023.0238
State	Published - Oct 1 2023

Funding

This study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (grant number 1UC4DK108612-01), by an Investigator-Initiated Study award from Novo Nordisk, and by Beta Bionics, Inc., which also provided the bionic pancreas devices used in the study. Fast-acting insulin aspart and insulin aspart were provided by Novo Nordisk and insulin lispro was provided by Eli Lilly. Blood glucose meters and test strips were provided by Ascensia Diabetes Care. Continuous glucose monitor sensors and transmitters were purchased from Dexcom, Inc., at a discounted price.

Keywords

Automated insulin delivery
Bionic pancreas
Patient-reported outcomes
Psychosocial
Type 1 diabetes

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology
Medical Laboratory Technology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1089/dia.2023.0238

Cite this

@article{b384479385954bd1bc095cb5b2e4fe78,

title = "Psychosocial Impact of the Insulin-Only iLet Bionic Pancreas for Adults, Youth, and Caregivers of Youth with Type 1 Diabetes",

abstract = "Objective: To evaluate the psychosocial impact and user experience for the insulin-only configuration of iLet bionic pancreas (BP) in persons 6–83 years years of age with type 1 diabetes. Research Design and Methods: In this multicenter, randomized controlled, 13-week trial, 275 adults (221 randomly assigned to the BP group and 54 to the standard of care [SC] group) and 165 youth and their caregivers (112 randomly assigned to the BP group and 53 to the SC group) completed psychosocial questionnaires at baseline, mid-study, and the end of the trial. Results: In all age groups, most participants would recommend using the BP, including those with previous experience using automated insulin delivery devices. Similarly, the vast majority of participants reported a high level of perceived benefits and a low number of perceived burdens. Adult participants reported significant decreases in the fear of hypoglycemia and in diabetes-specific emotional distress, as well as improvements in their perceived well-being. Conclusion: Findings demonstrate acceptability, reduced burden, and positive psychosocial outcomes for adults. Children and teenagers also report high acceptability and reduced burden, but less clear improvements in psychosocial outcomes.",

keywords = "Automated insulin delivery, Bionic pancreas, Patient-reported outcomes, Psychosocial, Type 1 diabetes",

author = "\{the Bionic Pancreas Research Group\} and Jill Weissberg-Benchell and Vesco, \{Anthony T.\} and Jenna Shapiro and Peter Calhoun and Damiano, \{Edward R.\} and Russell, \{Steven J.\} and Zoey Li and El-Khatib, \{Firas H.\} and Ruedy, \{Katrina J.\} and Balliro, \{Courtney A.\} and Beck, \{Roy W.\}",

note = "Publisher Copyright: {\textcopyright} Mary Ann Liebert, Inc.",

year = "2023",

month = oct,

day = "1",

doi = "10.1089/dia.2023.0238",

language = "English (US)",

volume = "25",

pages = "705--717",

journal = "Diabetes Technology and Therapeutics",

issn = "1520-9156",

publisher = "Mary Ann Liebert Inc.",

number = "10",

}

TY - JOUR

T1 - Psychosocial Impact of the Insulin-Only iLet Bionic Pancreas for Adults, Youth, and Caregivers of Youth with Type 1 Diabetes

AU - the Bionic Pancreas Research Group

AU - Weissberg-Benchell, Jill

AU - Vesco, Anthony T.

AU - Shapiro, Jenna

AU - Calhoun, Peter

AU - Damiano, Edward R.

AU - Russell, Steven J.

AU - Li, Zoey

AU - El-Khatib, Firas H.

AU - Ruedy, Katrina J.

AU - Balliro, Courtney A.

AU - Beck, Roy W.

PY - 2023/10/1

Y1 - 2023/10/1

N2 - Objective: To evaluate the psychosocial impact and user experience for the insulin-only configuration of iLet bionic pancreas (BP) in persons 6–83 years years of age with type 1 diabetes. Research Design and Methods: In this multicenter, randomized controlled, 13-week trial, 275 adults (221 randomly assigned to the BP group and 54 to the standard of care [SC] group) and 165 youth and their caregivers (112 randomly assigned to the BP group and 53 to the SC group) completed psychosocial questionnaires at baseline, mid-study, and the end of the trial. Results: In all age groups, most participants would recommend using the BP, including those with previous experience using automated insulin delivery devices. Similarly, the vast majority of participants reported a high level of perceived benefits and a low number of perceived burdens. Adult participants reported significant decreases in the fear of hypoglycemia and in diabetes-specific emotional distress, as well as improvements in their perceived well-being. Conclusion: Findings demonstrate acceptability, reduced burden, and positive psychosocial outcomes for adults. Children and teenagers also report high acceptability and reduced burden, but less clear improvements in psychosocial outcomes.

AB - Objective: To evaluate the psychosocial impact and user experience for the insulin-only configuration of iLet bionic pancreas (BP) in persons 6–83 years years of age with type 1 diabetes. Research Design and Methods: In this multicenter, randomized controlled, 13-week trial, 275 adults (221 randomly assigned to the BP group and 54 to the standard of care [SC] group) and 165 youth and their caregivers (112 randomly assigned to the BP group and 53 to the SC group) completed psychosocial questionnaires at baseline, mid-study, and the end of the trial. Results: In all age groups, most participants would recommend using the BP, including those with previous experience using automated insulin delivery devices. Similarly, the vast majority of participants reported a high level of perceived benefits and a low number of perceived burdens. Adult participants reported significant decreases in the fear of hypoglycemia and in diabetes-specific emotional distress, as well as improvements in their perceived well-being. Conclusion: Findings demonstrate acceptability, reduced burden, and positive psychosocial outcomes for adults. Children and teenagers also report high acceptability and reduced burden, but less clear improvements in psychosocial outcomes.

KW - Automated insulin delivery

KW - Bionic pancreas

KW - Patient-reported outcomes

KW - Psychosocial

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85171982342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85171982342&partnerID=8YFLogxK

U2 - 10.1089/dia.2023.0238

DO - 10.1089/dia.2023.0238

M3 - Article

C2 - 37523175

AN - SCOPUS:85171982342

SN - 1520-9156

VL - 25

SP - 705

EP - 717

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

IS - 10

ER -

Psychosocial Impact of the Insulin-Only iLet Bionic Pancreas for Adults, Youth, and Caregivers of Youth with Type 1 Diabetes

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this